INTRODUCTION: The WHO MDT for leprosy treatment was officially introduced in Brazil in 1991 and comprises three drugs: dapsone, rifampicin and clofazimine. There are few good studies on the frequency of side-effects attributable to MDT in Brazil. METHODS: A retrospective and descriptive study carried out in a LCP in Vitória, State of Espirito Santo, Brazil. A specific and detailed protocol about side-effects was prepared and filled in from the patient records. RESULTS: One hundred ninety four patients' records were analysed looking for side-effects attributable to MDT. Side-effects were attributed to at least one MDT component in 88 (45%) patients and 85 had side-effects due to dapsone, 24 due to rifampicin and 18 due to clofazimine. 185 episodes were identified. The suspected drug was stopped in 47 out of 88 episodes (24% patients); 46 had dapsone stopped, 5 had rifampicin stopped and no-one had clofazimine stopped. CONCLUSION: Side-effects attributed to MDT is more frequent than previously described, resulting in interruption of treatment in many patients.
INTRODUCTION: The WHO MDT for leprosy treatment was officially introduced in Brazil in 1991 and comprises three drugs: dapsone, rifampicin and clofazimine. There are few good studies on the frequency of side-effects attributable to MDT in Brazil. METHODS: A retrospective and descriptive study carried out in a LCP in Vitória, State of Espirito Santo, Brazil. A specific and detailed protocol about side-effects was prepared and filled in from the patient records. RESULTS: One hundred ninety four patients' records were analysed looking for side-effects attributable to MDT. Side-effects were attributed to at least one MDT component in 88 (45%) patients and 85 had side-effects due to dapsone, 24 due to rifampicin and 18 due to clofazimine. 185 episodes were identified. The suspected drug was stopped in 47 out of 88 episodes (24% patients); 46 had dapsone stopped, 5 had rifampicin stopped and no-one had clofazimine stopped. CONCLUSION: Side-effects attributed to MDT is more frequent than previously described, resulting in interruption of treatment in many patients.
Authors: José Wilton Queiroz; Gutemberg H Dias; Maurício Lisboa Nobre; Márcia C De Sousa Dias; Sérgio F Araújo; James D Barbosa; Pedro Bezerra da Trindade-Neto; Jenefer M Blackwell; Selma M B Jeronimo Journal: Am J Trop Med Hyg Date: 2010-02 Impact factor: 2.345
Authors: Rossilene Conceição da Silva Cruz; Samira Bührer-Sékula; Gerson Oliveira Penna; Maria Elisabete Amaral de Moraes; Heitor de Sá Gonçalves; Mariane Martins de Araújo Stefani; Maria Lúcia Fernandes Penna; Maria Araci de Andrade Pontes; Sinésio Talhari Journal: An Bras Dermatol Date: 2018-06 Impact factor: 1.896
Authors: Yunzhao R Ren; Fan Pan; Suhel Parvez; Andrea Fleig; Curtis R Chong; Jing Xu; Yongjun Dang; Jin Zhang; Hongsi Jiang; Reinhold Penner; Jun O Liu Journal: PLoS One Date: 2008-12-23 Impact factor: 3.240